BlackRock
KALV

BlackRock’s KalVista Pharmaceuticals KALV Stock Holding History

BlackRock’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,795,897
Closed -$76.4M – 5809
2026
Q1 		$76.4M Buy
3,795,897
+41,749
+1% +$673K ﹤0.01% 2267
2025
Q4 		$60.6M Buy
3,754,148
+628,031
+20% +$8.32M ﹤0.01% 2400
2025
Q3 		$38.1M Sell
3,126,117
-3,377
-0.1% -$46.7K ﹤0.01% 2672
2025
Q2 		$35.4M Sell
3,129,494
-22,241
-0.7% -$272K ﹤0.01% 2667
2025
Q1 		$36.4M Buy
3,151,735
+287,739
+10% +$2.94M ﹤0.01% 2559
2024
Q4 		$24.3M Sell
2,863,996
-198,323
-6% -$2.05M ﹤0.01% 2922
2024
Q3 		$35.5M Buy
3,062,319
+117,203
+4% +$1.47M ﹤0.01% 2682
2024
Q2 		$34.7M Buy
2,945,116
+512,882
+21% +$5.99M ﹤0.01% 2641
2024
Q1 		$28.8M Buy
2,432,234
+190,209
+8% +$2.54M ﹤0.01% 2782
2023
Q4 		$27.5M Buy
2,242,025
+597,278
+36% +$5.43M ﹤0.01% 2826
2023
Q3 		$15.8M Buy
1,644,747
+45,009
+3% +$460K ﹤0.01% 3074
2023
Q2 		$14.4M Buy
1,599,738
+41,604
+3% +$384K ﹤0.01% 3227
2023
Q1 		$12.2M Sell
1,558,134
-14,287
-0.9% -$107K ﹤0.01% 3205
2022
Q4 		$10.6M Sell
1,572,421
-133,727
-8% -$716K ﹤0.01% 3369
2022
Q3 		$24.8M Buy
1,706,148
+34,653
+2% +$484K ﹤0.01% 2913
2022
Q2 		$16.4M Buy
1,671,495
+127,468
+8% +$1.41M ﹤0.01% 3192
2022
Q1 		$22.8M Buy
1,544,027
+39,407
+3% +$566K ﹤0.01% 3096
2021
Q4 		$19.9M Buy
1,504,620
+87,978
+6% +$1.4M ﹤0.01% 3276
2021
Q3 		$24.7M Sell
1,416,642
-9,780
-0.7% -$198K ﹤0.01% 3146
2021
Q2 		$34.2M Sell
1,426,422
-133,066
-9% -$3.48M ﹤0.01% 2950
2021
Q1 		$40.1M Buy
1,559,488
+446,108
+40% +$11.7M ﹤0.01% 2770
2020
Q4 		$21.1M Buy
1,113,380
+198,646
+22% +$3.41M ﹤0.01% 2977
2020
Q3 		$11.5M Sell
914,734
-9,117
-1% -$114K ﹤0.01% 3147
2020
Q2 		$11.2M Buy
923,851
+51,394
+6% +$547K ﹤0.01% 3120
2020
Q1 		$6.67M Buy
872,457
+11,824
+1% +$160K ﹤0.01% 3211
2019
Q4 		$15.3M Buy
860,633
+94,121
+12% +$1.23M ﹤0.01% 3025
2019
Q3 		$8.89M Buy
766,512
+29,730
+4% +$480K ﹤0.01% 3270
2019
Q2 		$16.3M Buy
736,782
+666,525
+949% +$15.6M ﹤0.01% 2960
2019
Q1 		$2.01M Buy
70,257
+25,179
+56% +$546K ﹤0.01% 3702
2018
Q4 		$891K Buy
45,078
+25,769
+133% +$518K ﹤0.01% 3923
2018
Q3 		$427K Buy
19,309
+3,104
+19% +$42K ﹤0.01% 4159
2018
Q2 		$132K Buy
16,205
+10,871
+204% +$96K ﹤0.01% 4407
2018
Q1 		$50K Buy
5,334
+368
+7% +$3.85K ﹤0.01% 4432
2017
Q4 		$49K Buy
4,966
+236
+5% +$2.46K ﹤0.01% 4438
2017
Q3 		$32K Buy
4,730
+399
+9% +$2.85K ﹤0.01% 4527
2017
Q2 		$32K Buy
4,331
+913
+27% +$6.71K ﹤0.01% 4587
2017
Q1 		$27K Buy
+3,418
New +$25.7K ﹤0.01% 4561

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BlackRock's KALV Position: Q2 2026 in Review

BlackRock sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 3,795,897 shares — an estimated $76.4M sold.

BlackRock first reported a position in KALV in Q1 2017 and held it in 37 quarters. The position peaked at $76.4M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • BlackRock reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • BlackRock sold 3,795,897 KalVista Pharmaceuticals shares in Q2 2026, an estimated $76.4M.
  • BlackRock first reported a position in KalVista Pharmaceuticals in Q1 2017 and held it in 37 quarters.
  • BlackRock's KalVista Pharmaceuticals position peaked at $76.4M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.